HLX02

trastuzumab biosimilar · Shanghai Henlius Biotech

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HLX02, covering 2024-05-17 to 2024-05-17. Get the full timeline:

Most recent: Clinical Trial Update: Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer [Phase 3]

See pricing